Video

Dr. Jadvar shares highlights of appropriate use criteria for PSMA PET imaging

Author(s):

Urology Times staff

“PSMA is a very exciting development in the field of nuclear medicine,” says Hossein Jadvar, MD, PhD.

In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, provides an overview of the appropriate use criteria that he helped to develop for prostate-specific membrane antigen PET imaging. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Robert Jansen, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Bridget Lang Findlay, MD, answers a question during a Zoom video interview
Related Content
3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 1st 2025

Enrollment goal met in trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11 PET/CT

Hannah Clarke
The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
August 1st 2025

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Trial launches of diagnostic agent for clear cell renal cell carcinoma
August 1st 2025

Trial launches of diagnostic agent for clear cell renal cell carcinoma

Hannah Clarke
Arm D of the trial is assessing the performance of [68Ga]Ga-DPI-4452 in detecting ccRCC in patients with an indeterminate renal mass.
FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting
August 1st 2025

FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting

Hannah Clarke Jason M. Broderick
The label expansion follows the FDA approval of an expanded label for 177Lu-PSMA-617 for use in patients with mCRPC after ARPI therapy and before chemotherapy.
3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 1st 2025

64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence

Hannah Clarke
The results from the SABRE trial are intended to support the design of a registrational trial of 64Cu-SAR-Bombesin.
PSMA-PET imaging product, Gozellix, launches on US market
August 1st 2025

PSMA-PET imaging product, Gozellix, launches on US market

Hannah Clarke
Gozellix was approved by the FDA in March 2025.
© 2025 MJH Life Sciences

All rights reserved.